SANOFI INDIA
|
|
BOM : 500674     NSE : SANOFI     | |
LT :  
    Long Term Analysis
Fundamentals : Good
Valuation : Average [Stock is fairly valued] Debt : Low |
Updated: |
ST :  
    Short Term Analysis
Quarterly Earnings Trend : Upward
Price Momentum : Upward Pledged Shares : None or < 25% |
Mar 27,2025 |
Price(EOD): ₹ 5,831.10
This is the End-of-Day (EOD) Stock Price updated daily by 7 pm IST.
|
Pharmaceuticals & Drugs |
MCap: ₹ 13,411.53 Cr |
Industry Peers & Returns | 1W | 1M | 1Y |
SANOFI INDIA | -0.8% | 14.8% | -21.3% |
SUN PHARMACEUTICAL INDUSTRIES | -3% | 5.6% | 9.3% |
DIVIS LABORATORIES | 1% | 2.7% | 70.3% |
CIPLA | -2.7% | 0.4% | -0.4% |
TORRENT PHARMACEUTICALS | 0.1% | 7.2% | 25.7% |
DR REDDYS LABORATORIES | -3.1% | -0.2% | -6.2% |
MANKIND PHARMA | 2% | 7.1% | 8.8% |
ZYDUS LIFESCIENCES | -3% | 0.1% | -9.3% |
LUPIN | -4.6% | 6.1% | 28% |
FUNDAMENTAL ANALYSIS OF SANOFI INDIA
 Y : Last Audited Annual/Yearly Data
TTM i.e. Trailing Twelve Months is calculated using last 4 quarterly data and is a good substitute to track last 4 Qtr Annual result before the subsequent year data is published and audited.
Learn More
VALUATION OF SANOFI INDIA
 Ratio | Standalone | |
---|---|---|
P/E P/B P/S |
35.5
P/E Calculated based on Trailing Twelve Months (TTM) Earnings of Rs 378.30 Cr
[Latest Qtr - Dec2024 - Standalone Results ] 15.6
P/B Calculated based on Book Value of Rs 860.60 Cr
[Latest Year - Dec2024 - Standalone Results ] 6.01
P/S Calculated based on Trailing Twelve Months (TTM) Revenues of Rs 0.00 Cr
[Latest Qtr - Dec2024 - Standalone Results ] |
|
Financial Ratios → |
Model | Discount(-)/ Premium(+) |
---|---|
EV/EBIDTA EV/Sales Price/Sales |
-11% 10% 9% |
SHARE PRICE MOMENTUM OF SANOFI INDIA
SANOFI INDIA vs SENSEX
DEBT OF SANOFI INDIA
Year | Debt/Equity ratio | |
---|---|---|
Standalone | Consolidated | |
2024 2023 2022 Avg_3yrs |
- 0 0 - |
- - - - |
[Last Annual Data : Dec2023]
|
||
Financial Ratios → |
PLEDGED PROMOTER SHARES OF SANOFI INDIA
Pledged Promoter Shares |
0 % | |
---|---|---|
As on : Dec2024 | ||
If less than 25% | Good |
|
If between 25% and 50% | Neutral | |
If greater than 50% | Bad | |
Shareholding Pattern → |
QTRLY RESULTS OF SANOFI INDIA
Standalone | Q-o-Q | Y-o-Y |
---|---|---|
Revenue Op Profit Profit Before Tax Profit After Tax |
-1.74% -1.17% 8.53% 11.07% |
9.74% 18.78% 23.06% 30.99% |
QtrlyTrend |
4 | |
Latest Qtr: Dec2024 | ||
Quarterly Result Analysis → |
SANOFI INDIA related INDICES
BSE Indices | 1W | 1M | 1Y |
---|---|---|---|
BSE ALLCAP | 3.8% | 3.5% | 9.2% |
BSE 500 | 1.6% | 3.6% | 7.1% |
BSE 500 SHARIAH | 1.6% | 0.1% | 1.9% |
BSE 250 SMALLCAP INDEX | 1.4% | 2.9% | 6.7% |
BSE 400 MIDSMALLCAP INDEX | 1.3% | 3.3% | 9.4% |
NSE Indices | 1W | 1M | 1Y |
---|---|---|---|
NIFTY 500 | 1.6% | 3.5% | 7.6% |
NIFTY TOTAL MARKET | 1.5% | 3.4% | 7.7% |
NIFTY500 MULTICAP 50:25:25 | 1.5% | 3.3% | 8.3% |
NIFTY500 LARGEMIDSMALL EQUAL-CAP WEIGHTED INDEX | 1.4% | 3.1% | NA |
NIFTY 500 EQUAL WEIGHT | 1.4% | 2.9% | NA |
You may also like the below Video Courses
FAQ about SANOFI INDIA
Is SANOFI INDIA good for long term investment?
As on Mar 27,2025, the Fundamentals of SANOFI INDIA look Strong and hence it may be good for long term investment! See Financial Performance of SANOFI INDIA . Please look at the other parameters such as Valuation, Price Momentum, News & Corporate Governance and/or consult an Investment Advisor before taking an investment decision!Is SANOFI INDIA UnderValued or OverValued?
As on Mar 27,2025, SANOFI INDIA is Fairly Valued based on the estimates of intrinsic value and investors may wait for the buying opportunity once it becomes under valued!What is the Intrinsic Value of SANOFI INDIA ?
As on Mar 27,2025, the Intrinsic Value of SANOFI INDIA is Rs. 5,361.52 estimated based on Median of the 3 historical models.Fair Value [Median EV / EBIDTA Model] : Rs. 6,569.35
Fair Value [Median EV / Sales Model] : Rs. 5,286.74
Fair Value [Median Price / Sales Model] : Rs. 5,361.52
Estimated Median Fair Value of SANOFI INDIA : Rs. 5,361.52
The fair value of any stock is always subjective and should, in no way, be taken as a recommendation to buy/sell the same.